Programmatic Management of Drug-Resistant Tuberculosis: An Updated Research Agenda.
Carole D MitnickCarly A RodriguezMarita L HattonGrania BrigdenFrank CobelensMartin P GrobuschRobert HorsburghChristoph LangeChristian LienhardtEyal OrenLaura J PodewilsBarbara SeaworthSusan van den HofCharles L DaleyAgnes C GebhardFraser Waresnull nullPublished in: PloS one (2016)
There is continuity around the priorities for research in PMDT. Coordinated efforts to address questions regarding shorter treatment regimens, knowledge of disease burden without representative data, and treatment for LTBI in contacts of known DR-TB patients are essential to stem the epidemic of TB, including DR-TB.
Keyphrases
- drug resistant
- mycobacterium tuberculosis
- multidrug resistant
- end stage renal disease
- healthcare
- acinetobacter baumannii
- newly diagnosed
- machine learning
- patient reported outcomes
- pseudomonas aeruginosa
- editorial comment
- big data
- electronic health record
- cystic fibrosis
- risk factors
- hiv aids
- deep learning
- artificial intelligence
- hiv infected
- data analysis
- patient reported